Stockscreener 앱 받기
0.61%
시간 외 거래:
전일 마감가:
$26.43
열려 있는:
$26.42
하루 거래량:
47.59M
Relative Volume:
1.01
시가총액:
$149.36B
수익:
$63.83B
순이익/손실:
$10.77B
주가수익비율:
13.97
EPS:
1.8799
순현금흐름:
$12.44B
1주 성능:
+3.10%
1개월 성능:
+5.59%
6개월 성능:
+16.08%
1년 성능:
-10.03%
1일 변동 폭
$26.05
$26.58
1주일 범위
$25.58
$27.69
52주 변동 폭
$20.91
$30.43
화이자 Stock (PFE) Company Profile
명칭
Pfizer Inc
전화
(212) 733-2323
주소
66 HUDSON BOULEVARD EAST, NEW YORK, NY
PFE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
26.27 | 150.27B | 63.83B | 10.77B | 12.44B | 1.8799 |
|
LLY
Lilly Eli Co
|
843.63 | 757.55B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
188.89 | 453.15B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
232.83 | 406.64B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
131.55 | 256.02B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
87.61 | 221.80B | 63.43B | 16.42B | 14.72B | 6.4861 |
화이자 Stock (PFE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-25 | 재개 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | 다운그레이드 | Argus | Buy → Hold |
| 2024-02-23 | 개시 | Guggenheim | Buy |
| 2024-01-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-10-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-17 | 재확인 | JP Morgan | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-06-29 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-01-17 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-20 | 재확인 | Cowen | Outperform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-13 | 업그레이드 | UBS | Neutral → Buy |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-12-16 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 재개 | Goldman | Neutral |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-10-12 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-16 | 개시 | SVB Leerink | Mkt Perform |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-27 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-07-30 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 재개 | Morgan Stanley | Overweight |
| 2019-02-20 | 재개 | Citigroup | Neutral |
| 2019-01-31 | 업그레이드 | Argus | Hold → Buy |
| 2019-01-31 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | 다운그레이드 | UBS | Buy → Neutral |
| 2018-12-11 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-01 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
모두보기
화이자 주식(PFE)의 최신 뉴스
TrumpRx Brings Pfizer Into the Green—Is It a Buy? - MarketBeat
Commentary: There's much less than meets the eye in Trump's 'historic' drug price deal with Pfizer - Los Angeles Times
Pfizer 2025: Old reliable - PharmaLive
Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal - Investing.com
Pfizer Offers High Yield And Capital Appreciation Opportunities (Technical Analysis) (PFE) - Seeking Alpha
Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal - sharewise.com
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Pfizer Stock Soars After Trump’s Drug Deal and Obesity Bet – Is This the Start of a Comeback? - ts2.tech
AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week? - The Globe and Mail
Zacks Value Trader Highlights: Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk - The Globe and Mail
Catheter Related Bloodstream Infections Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Xellia Pharma, Pfizer, Glenmark Pharma, Fresenius Medical Care - Barchart.com
A Wave of New Apartment Buildings Are Set to Take Over Midtown Manhattan - Bloomberg.com
Trump administration could lower drug prices by making other nations pay more - PharmaVoice
Great News for Pfizer Stock Investors - Nasdaq
4 Reasons to Buy Pharma ETFs Now for a Healthy Portfolio - Yahoo Finance
3 Reasons to Buy Pfizer Stock Now - Nasdaq
Pfizer (PFE) Stands Out as Top Big Pharma Pick - GuruFocus
Opinion | Meet Albert Bourla—Pfizer CEO, Diplomat and Actor - The Wall Street Journal
Trump unveils TrumpRx; Pfizer to offer discounted drugs after 100% tariff threat - CBS News
3 Dirt Cheap Stocks to Buy in a Market Priced for Perfection - The Globe and Mail
Is Pfizer Inc. (PFE) the Best Non-Tech Stock to Buy Now for Long Term? - MSN
Can Pfizer's Stock Break This Disappointing Streak? - AOL.com
Bank of America Securities Maintains Buy on Pfizer Inc (PFE) - Yahoo Finance
President Trump was undaunted getting Pfizer deal: Dr. Oz - NewsNation
Pfizer (PFE) Surges Following Landmark Drug Pricing Deal - GuruFocus
Pfizer – TrumpRx deal boosts Big Pharma to a record rally - Seeking Alpha
Pfizer’s AI Revolution: A New Era for Drug Discovery and Pharmaceutical Innovation - FinancialContent
Tech stocks roll on and Pfizer soars after Trump deal - Yahoo Finance
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know - sharewise.com
5 Large Cap Drug Stocks: Values or Traps? - The Globe and Mail
The Score: Pfizer, Tesla, Electronic Arts and More Stocks That Defined the Week - MSN
B of A Securities Maintains Pfizer (PFE) Neutral Recommendation - Nasdaq
Pharma Stocks Eye Best Week in 16 Years as Trump Overhang Eases - Bloomberg.com
Wall Street Hits Record Highs As Rate Cut Bets Offset Shutdown: This Week In MarketsPfizer (NYSE:PFE) - Benzinga
What TrumpRx Means for Pfizer Stock and Pharma Investors - Stansberry Research
How Trump’s 100% Tariff Threat Forced Pfizer’s Hand — Inside The High-Stakes Talks That Changed Big Pharma’s Course - Stocktwits
Pfizer (PFE) Experiences Bullish Activity as Options Volume Surges - GuruFocus
Gallego demands transparency in Trump’s deal with Pfizer - The Hill
Trump administration announces MFN drug pricing deal with Pfizer - Yahoo Finance
Pink Sheet Podcast: Government Shutdown’s Impact On US FDA, Pfizer Inks Drug Pricing Deal - insights.citeline.com
Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump? - The Globe and Mail
MRK Stock Up Nearly 14% So Far This Week: What's Driving It? - The Globe and Mail
Pfizer’s drug-price deal with Trump ended months of deadlock - The Edge Malaysia
Weekly Rundown: TrumpRx unveils direct-to-consumer platform, Pfizer on board - Drug Discovery News
Pfizer (PFE) Is Up 14.7% After Landmark U.S. Drug Pricing and Tariff Exemption Deal - Yahoo Finance
Shareholders 26% loss in Pfizer (NYSE:PFE) partly attributable to the company's decline in earnings over past three years - Yahoo Finance
How Trump Finally Cut a Deal With Big Pharma - Bloomberg.com
Pfizer (PFE) Secures Deal to Avert Tariffs Through U.S. Manufact - GuruFocus
Cantor Fitzgerald Maintains a Hold on Pfizer (PFE) - Yahoo Finance
MAHA supporters not on board with Trump’s Pfizer deal - The Hill
Eli Lilly And Its Competitors Pop On The Pfizer News - Real Investment Advice
화이자 (PFE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.82%
1.04%
자본화:
|
볼륨(24시간):